Efficacy of Recombinant Human Interferon Alpha-2b Vaginal Effervescent Capsule Combined with Lactobacillus Vaginal Capsule in the Treatment of Cervical HPV Infection
WANG Xiujuan
Beijing Aerospace General Hospital, Beijing 100076, China
Abstract：Objective: To observe the efficacy of recombinant human interferon alpha-2b vaginal effervescent capsule combined with Lactobacillus vaginal capsule in the treatment of cervical HPV infection and the improvement of vaginal microecology. Methods: The subjects were selected from May 2016 to May 2018 in our hospital for the treatment of cervical high-risk HPV infection, including 140 cases. According to the different treatments, they were randomly divided into control group (70 cases) and treatment group (70 cases). Patients in the control group were given recombinant human interferon alpha-2b vaginal effervescent capsules, one capsule per day for a course of 10 days within a total of three courses of treatment. For the treatment group, Lactobacillus vaginal capsules were taken on the basis of the treatment of the control group, once a night for a course of 7 days within four courses of treatment; after one month of treatment, the effect of treatment was evaluated accordingly. The main method of evaluation is to reexamine the vaginal microorganisms of patients, at the same time to reexamine the cervical HPV negative transformation of patients, and to reexamine the expression of immunoinflammatory factors. Results: After treatment, 44 cases in the treatment group turned negative, and the effective rate was 90% (19 cases ), while 34 cases in the control group turned negative, 17 cases effective; the difference between the two groups was significant (P<0.05). After treatment of a month, for the treatment group, 64 cases of vaginal microbes returned to normal, with a return to normal rate of 91.4%, while 43 cases in the control group returned to normal, with a return to normal rate of 61.4%. The pH value of vaginal secretion in the treatment group was 4.1±0.6) and that in the control group was 4.6±0.7). The normal vaginal PH value was restored in the treatment group. Nugent score of the two groups was (2.2 ±0.4) in the treatment group, which was lower than (2.9 + 0.8) in the control group. There was a significant difference between the two groups (P<0.05). After one month of treatment, IL-4 decreased significantly in both groups, while IL-12 and IFN-gamma increased significantly in both groups. Compared with the control group, the treatment group had a much larger extent (P<0.05). Conclusion: Recombinant human interferon alpha-2b vaginal effervescent capsule combined with Lactobacillus vaginal capsule is effective in the treatment of cervical HPV infection and can improve vaginal microecosystem.
王秀娟. 重组人干扰素α-2b阴道泡腾胶囊联合乳酸菌阴道胶囊治疗宫颈HPV感染的疗效[J]. 河北医学, 2021, 27(4): 678-682.
WANG Xiujuan. Efficacy of Recombinant Human Interferon Alpha-2b Vaginal Effervescent Capsule Combined with Lactobacillus Vaginal Capsule in the Treatment of Cervical HPV Infection. HeBei Med, 2021, 27(4): 678-682.
2021, Vol. 27 
冀公网安备13080202000677号